Skip to main content

Table 1 Tumor models, mouse hosts, CPA schedules, gene responses and UPR analysis. RNA-seq was performed on two replicated RNA pools for each condition (Additional file 1: Table S1 legend)

From: Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators

  Responsive tumors Unresponsive tumors
Tumor GL261 LLC B16F10
Mouse host B6 scid scid scid B6 B6
CPA schedule (days) 6 6 9 6 and 9a 6 6
Tumor responses to CPA treatment Complete regression Major regression with late rebound Major regression with early rebound Minor growth delay Moderate growth delay
Up regulated genes 2119 2574 2713 2352 151 663
Down regulated genes 809 1250 1564 1176 70 394
Stringent Upstream Regulators (UPRs) 180 210 218 179 6 93
  1. Shown here is a summary of tumor responses to drug treatment, for GL261(B6) [20], GL261(scid) [18], LLC and B16F10 tumors (Fig. 1), the number of genes up or down regulated at |FC| > 2 and p < 0.001 (Additional file 1: Table S1), and the number of significant UPRs (Additional file 4: Table S3) after filtering of the full set of UPRs output by IPA (Additional file 3: Table S2)
  2. a, Number of commonly regulated genes and UPRs responding in common between GL261(scid) tumors treated with CPA/6d and GL261(scid) tumors treated with CPA/9d